Engineering innovative solutions to screen for prostate cancer

The search for non-invasive tools for the diagnosis and management of cancer has long been a major goal of cancer research. Cost-effective technologies for blood-based, sensitive and specific detection of nucleic acid biomarkers could potentially transform the way cancer is diagnosed and treated. Ci...

Full description

Saved in:
Bibliographic Details
Published in:Convergent science physical oncology 2017-02, Vol.3 (1), p.16001
Main Authors: Al Sulaiman, Dana, Metcalf, Gavin A D, Ladame, Sylvain
Format: Article
Language:English
Subjects:
biomarkers
biosensors
early diagnosis
microRNA
prostate cancer
public screening
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The search for non-invasive tools for the diagnosis and management of cancer has long been a major goal of cancer research. Cost-effective technologies for blood-based, sensitive and specific detection of nucleic acid biomarkers could potentially transform the way cancer is diagnosed and treated. Circulating microRNAs in blood have recently emerged as clinically useful and minimally invasive predictive, diagnostic and prognostic biomarkers for prostate cancer. However, they are very challenging to detect accurately due to their low concentration and high sequence homology. Herein we highlight the main limitations of the current gold-standard technologies for microRNA detection (including complexity and cost) and discuss recent technological advances toward new blood tests suitable for widespread public screening.
ISSN:2057-1739
2057-1739
DOI:10.1088/2057-1739/aa5ebe